• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

37.11 +0.31 (+0.84%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
2 Reasons to Watch RPRX and 1 to Stay Cautious
July 30, 2025
Royalty Pharma has had an impressive run over the past six months as its shares have beaten the S&P 500 by 11.3%. The stock now trades at $36.72, marking a 16.2% gain. This was partly thanks to its... 
Via StockStory
Topics Stocks
3 Profitable Stocks to Research Further
July 28, 2025
Companies with solid operating margins have a competitive edge, allowing them to reinvest for sustainable expansion. The best of these businesses balance profitability with reinvestment, setting... 
Via StockStory
Topics Supply Chain
Royalty Pharma Declares Third Quarter 2025 Dividend
July 18, 2025
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company’s Board of Directors
July 17, 2025
From Royalty Pharma plc
Via GlobeNewswire
A Look Into Royalty Pharma Inc's Price Over Earnings
June 23, 2025
 
Via Benzinga
Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025
July 16, 2025
From Royalty Pharma plc
Via GlobeNewswire
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today
July 09, 2025
 
Via Benzinga
2 Surging Stocks to Research Further and 1 to Be Wary Of
June 26, 2025
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial... 
Via StockStory
Revolution Medicines To Advance Lead Cancer Drug With $2 Billion In Funds
June 24, 2025
Revolution Medicines signs a $2 billion funding deal with Royalty Pharma to support its RAS(ON) pipeline, including daraxonrasib development and launch. 
Via Benzinga
How Is The Market Feeling About Royalty Pharma?
June 19, 2025
 
Via Benzinga
Earnings Scheduled For May 8, 2025
May 08, 2025
 
Via Benzinga
Revolution Medicines To Get Up To $2B For Development Of Cancer Drug From Royalty Pharma
June 24, 2025
Royalty Pharma will provide up to $1.25 billion to Revolution Medicines in exchange for a synthetic royalty on annual worldwide net sales of Daraxonrasib for a term of 15 years and a senior secured... 
Via Stocktwits
Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion
June 24, 2025
From Royalty Pharma plc
Via GlobeNewswire
Q1 Rundown: Royalty Pharma (NASDAQ:RPRX) Vs Other Branded Pharmaceuticals Stocks
June 18, 2025
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Royalty Pharma (NASDAQ:RPRX) and the best... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
RPRX Q1 Earnings Call: Flat Revenue, Portfolio Expansion, and Capital Return Initiatives
June 09, 2025
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) met the market’s revenue expectations in Q1 CY2025, with sales flat year on year at $568.2 million. Its non-GAAP EPS of $1.06 per share was... 
Via StockStory
2 Value Stocks to Target This Week and 1 to Turn Down
June 06, 2025
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few... 
Via StockStory
Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
June 04, 2025
From Royalty Pharma plc
Via GlobeNewswire
1 Stock Under $50 with Competitive Advantages and 2 to Question
June 04, 2025
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to... 
Via StockStory
12 Health Care Stocks Moving In Friday's After-Market Session
May 23, 2025
 
Via Benzinga
Royalty Pharma Completes the Acquisition of Its External Manager
May 16, 2025
From Royalty Pharma plc
Via GlobeNewswire
3 of Wall Street’s Favorite Stocks with Mounting Challenges
May 15, 2025
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
Royalty Pharma to Present at Upcoming Investor Conferences
May 13, 2025
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition
May 12, 2025
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma (NASDAQ:RPRX) Posts Q1 Sales In Line With Estimates
May 08, 2025
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) met Wall Street’s revenue expectations in Q1 CY2025, but sales were flat year on year at $568 million. Its GAAP profit of $0.75 per share... 
Via StockStory
Royalty Pharma Reports First Quarter 2025 Results
May 08, 2025
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma (RPRX) Reports Q1: Everything You Need To Know Ahead Of Earnings
May 07, 2025
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting results tomorrow before the bell. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
Royalty Pharma PLC - CL A (NASDAQ:RPRX) Shows Strong Technical Setup for Breakout Investors
May 01, 2025
Royalty Pharma PLC - CL A (NASDAQ:RPRX) Shows Strong Technical Setup for Breakout Investors 
Via Chartmill
ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) Technical Analysis observations.
May 01, 2025
Exploring ROYALTY PHARMA PLC- CL A's Technical Signals and Breakout Potential: Indications Suggest NASDAQ:RPRX Could Be on the Verge of a Breakout. 
Via Chartmill
3 Mid-Cap Stocks Facing Headwinds
April 24, 2025
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with... 
Via StockStory
Topics Economy
Royalty Pharma Declares Second Quarter 2025 Dividend
April 21, 2025
From Royalty Pharma plc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap